{
    "symbol": "ESPR",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-03 14:08:04",
    "content": " A positive cardiovascular outcome trial in 2023 not only has the potential to expand our current labeled indication, but also to be practice-changing for physicians and paradigm shifting for millions of patients around the world, advancing Esperion\u2019s mission of making cardiovascular risk reduction more accessible and convenient for all. Combined royalty and partner revenue of $5.5 million for the first quarter ended March 31, 2022, grew approximately 244% year-over-year, driven by launches in Belgium, Switzerland and the Netherlands, and continued growth in previously launched territories. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}